NEW YORK (GenomeWeb) – Contract research organization Cenix BioScience this week announced a research framework agreement with metabolite services and biomarker firm Metanomics Health.

As the first assignment, Cenix will perform a target validation project for Metanomics for an undisclosed disease indication. Cenix will use its expertise in high-content screening based on the Definiens XD image analysis platform for the comprehensive functional characterization of target genes designated by Metanomics, it said.

Financial and other terms of the deal were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.